期刊文献+

中药联合化疗治疗晚期原发性非小细胞肺癌疗效分析 被引量:11

Study on therapeutic effect of Chinese herbs combined with chemotherapy on advanced non-small cell lung cancer
暂未订购
导出
摘要 目的:探讨中西医结合对晚期非小细胞肺癌的治疗作用。方法:对68例晚期非小细胞肺癌患者给予中药辨证论治加化疗治疗(中西组,第Ⅰ组),并与51例单纯化疗(化疗组,第Ⅱ组)比较。中药辨证论治分为气虚痰湿型、气阴两虚型、阴虚内热型和痰阻血瘀型。结果:两组近期客观疗效相近,两组有效率(CR+PR)分别为45.6%,33.3%(P>0.05),但中西组的稳定率(CR+PR+NC)为79.4%,明显高于化疗组56.9%(P<0.01)。化疗后中西组患者生活质量评分明显高于化疗组(P<0.05),中位生存期中西组为10.6个月,化疗组为8.4个月。结论:中医辨证论治加化疗可提高晚期非小细胞肺癌患者的稳定率,改善生活质量,但中药与化疗结合并未能明显提高治疗有效率及远期生存率。 To observe the effect of traditional Chinese medicinal herbs combined with systemic chemotherapy on advanced non-small cell lung caneer(NSCLC). Methods :From May 2001 to December 2003,119 patients with advanced NSCLC were divided at random into two groups :group Ⅰ ,68 eases treated with traditional Chinese medicine combination with systemic chemotherapy,group Ⅱ ,51 cases treated with systemic chemotherapy alone. The protocol of chemotherapy used in the two groups was similar. Results:Effective rats(CR+PR) were 45.6% in group Ⅰ ,33.3% in group Ⅱ . There were no significant differences between these two groups according to the short term results(P〉0.05). Mean survival time(month)for group Ⅰ and group Ⅱ were 10.6 and 8.4 respectively. Stabi lize rates (CR +PR+ NC)(79.4 % ) of group Ⅰ was significantly higher than that of group Ⅱ (56.9% )(P〈20.01). Living quality of group Ⅰ was significantly higher than that of group Ⅱ (P〈0. 01). Conclusions :Chinese medicinal herbs combined with systemic chemotherapy were helpful to improve stabilize rates and living quality, However Chinese medicinal herbs combined with systemic chemotherapy did not improve the effective rats and survival rats.
出处 《临床医药实践》 2006年第6期409-411,共3页 Proceeding of Clinical Medicine
关键词 非小细胞肺癌 中医药 辨证论治 化疗 Non-small cell lung cancer Traditional Chinese medicine Treatment based on the differential diagno sis Systemic chemotherapy
  • 相关文献

参考文献7

二级参考文献27

  • 1方茵,田少雷,李克庆,赵树纬,王志远.抗肿瘤药物研究Ⅱ:去甲斑蝥素去氧脱氢类似物的合成与抗癌活性[J].药学学报,1993,28(12):931-935. 被引量:164
  • 2杨桦,金壮,赫甡,马占宝.人参皂甙与免疫核糖核酸对癌基因表达的协同抑制作用[J].中国医科大学学报,1993,22(4):255-258. 被引量:209
  • 3李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:227
  • 4郑莜萸主编.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.216-224.
  • 5孙传兴主编.I晦床疾病诊断治愈好转标准:第2版[M].北京:人民军医出版社,1998.63.
  • 6李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 7Paemans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small cell lung cancer: uni-and multivariate analysis including RECPAM in 1052 patients. J Clin Oncol 1995;13:1221-1230.
  • 8Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the subcommittee for the management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Reseach. Br J Cancer 1990;61:597-604.
  • 9Sagman U, Feld R, Evans WK, et al. The prognostic significance of pretrement serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oneol 1991;9:954-961.
  • 10Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate moded based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986;46:4189-4194.

共引文献557

同被引文献151

引证文献11

二级引证文献111

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部